GM1神經節苷脂貯積病治療的全球市場:各產品類型，各疾病類型，各地區 - 規模，佔有率，展望，機會分析(2022年～2028年)

全球GM1神經節苷脂貯積病治療市場上，主要企業為了提高存在感，著重策略性協定。

本報告提供全球GM1神經節苷脂貯積病治療市場相關調查分析，推動市場要素與阻礙因素，市場機會，COVID-19影響，各產品類型、疾病類型、地區的市場分析，競爭情形等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場範圍

• 報告的說明
• 市場定義和範圍
• 摘要整理
• 市場概述:各產品類型
• 市場概述:各疾病類型
• 市場概述:各地區
• Coherent Opportunity Map (COM)

第3章 市場動態、法規、趨勢分析

• 促進因素
• 阻礙因素
• 市場機會
• 影響分析
• 開發平台分析
• 法規情境
• 重要的開發
• 流行病學
• 1次調查的洞察
• 患者的洞察
• 醫生的洞察
• 製造商洞察

第4章 全球GM1神經節苷脂貯積病治療市場:COVID-19流行的影響

• 經濟影響
• 流行病學的COVID-19
• COVID-19對進行中的臨床試驗的影響

第5章 全球GM1神經節苷脂貯積病治療市場:各產品類型(2017年～2028年)

• 簡介
• 市場佔有率分析
• 與前一年同期比較成長率分析
• 市場區隔趨勢

第6章 全球GM1神經節苷脂貯積病治療市場:各疾病類型(2017年～2028年)

• 簡介
• 市場佔有率分析
• 與前一年同期比較成長率分析
• 市場區隔趨勢

第7章 全球GM1神經節苷脂貯積病治療市場:各地區(2017年～2028年)

• 簡介
• 北美
• 歐洲
• 其他地區

第8章 競爭情形

• 企業簡介
• Axovant Gene Therapies Ltd.
• Passage Bio
• Lysogene

GM1 gangliosidosis is a progressive neurological genetic disorder mainly caused by the absence of a vital enzyme known as beta-galactosidase (GLB1). Without GLB1, a fatty substance called GM1 gangliosidosis accumulates in cells, and nerve cells of the brain. GM1 gangliosidosis is one of the 50 genetically inherited disorders known as lysosomal storage diseases. Currently, there is no treatment or cure for treatment of GM1 gangliosidosis.

Market Dynamics

Key players are focusing on strategic agreements in order to expand their presence in the market. For instance, in May 2017, Lysogene entered a strategic manufacturing agreement with Brammer Bio, a viral gene and cell therapy manufacturer. The agreement is expected to help Brammer Bio manufacture LYS-GM101, an AAVrh10- based gene therapy for the treatment of GM1 gangliosidosis.

Key features of the study:

• This report studies the current scenario as well as the future potential of the global GM1 gangliosidosis market. The market for GM1 gangliosidosis is segmented on the basis of product type, disease type, and region.
• This report provides in-depth analysis of the global GM1 gangliosidosis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global GM1 gangliosidosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
• The global GM1 gangliosidosis market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global GM1 gangliosidosis market

Detailed Segmentation:

• Global GM1 Gangliosidosis Treatment Market, By Product Type :
  • LYS-GM101
  • PBGM01
  • AXO-AAV-GM1
• Global GM1 Gangliosidosis Treatment Market, By Disease Type :
  • Type 1 GM1 Gangliosidosis
  • Type 2 GM1 Gangliosidosis
  • Type 3 GM1 Gangliosidosis
• Global GM1 Gangliosidosis Treatment Market, By Region:
  • North America
    • By Product Type:
    • LYS-GM101
    • PBGM01
    • AXO-AAV-GM1
    • By Disease Type :
    • Type 1 GM1 Gangliosidosis
    • Type 2 GM1 Gangliosidosis
    • Type 3 GM1 Gangliosidosis
    • By Country:
    • U.S.
    • Canada
  • Europe
    • By Product Type:
    • LYS-GM101
    • PBGM01
    • AXO-AAV-GM1
    • By Disease Type :
    • Type 1 GM1 Gangliosidosis
    • Type 2 GM1 Gangliosidosis
    • Type 3 GM1 Gangliosidosis
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Rest of World
    • By Product Type:
    • LYS-GM101
    • PBGM01
    • AXO-AAV-GM1
    • By Disease Type :
    • Type 1 GM1 Gangliosidosis
    • Type 2 GM1 Gangliosidosis
    • Type 3 GM1 Gangliosidosis
    • By Region:
    • Latin America
    • Asia Pacific
    • Middle East
    • Africa.
• Company Profiles.
  • Axovant Gene Therapies Ltd. *
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Passage Bio
  • Lyosgene

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
• Market Definition and Scope
• Executive Summary
• Market Snapshot, By Product Type
• Market Snapshot, By Disease Type
• Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Drivers
• Restraints
• Market Opportunities
• Impact Analysis
• Pipeline Analysis
• Regulatory Scenario
• Key Development
• Epidemiology
• Primary Research Insights
• Patient Insights
• Physician Insights
• Manufacturer Insights

4. Global GM1 Glangliosidosis Treatment Market - Impact of COVID-19 Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact of COVID-19 on Ongoing Clinical Trials

5. Global GM1 Glangliosidosis Treatment Market, By Product Type, 2017 - 2028 (US$ Mn)

• Introduction
• Market Share Analysis, 2022 and 2028 (%)
• Y-o-Y Growth Analysis, 2017 - 2028
• Segment Trends
  • LYS-GM101
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • PBGM01
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • AXO-AAV-GM1
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global GM1 Glangliosidosis Treatment Market, By Disease Type, 2017 - 2028 (US$ Mn)

• Introduction
• Market Share Analysis, 2022 and 2028 (%)
• Y-o-Y Growth Analysis, 2017 - 2028
• Segment Trends
  • Type 1 GM1 Gangliosidosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Type 2 GM1 Gangliosidosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Type 3 GM1 Gangliosidosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global GM1 Glangliosidosis Treatment Market, By Region, 2017 - 2028 (US$ Mn)

• Introduction
• Market Share Analysis, By Country, 2022 and 2028 (%)
• Y-o-Y Growth Analysis, For Countries, 2017 - 2028
• North America
• Introduction
• Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • U.S.
  • Canada
• Europe
• Introduction
• Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Rest of World
• Introduction
• Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa.

8. Competitive Landscape

• Company Profiles
• Axovant Gene Therapies Ltd.
• Company Overview
• Clinical Trial Phase Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
• Passage Bio
• Company Overview
• Clinical Trial Phase Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
• Lysogene
• Company Overview
• Clinical Trial Phase Portfolio
• Financial Overview
• Key Highlights
• Market Strategies